Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
š¼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Legend Biotech Corp (LEGN US)
Watchlist
118
Analysis
Health Care
ā¢
China
Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
ā¢
Legend Biotech Corp
ā¢
01 Jun 2020 14:59
Legend Biotech (ä¼ å„ēē©) Pre-IPO: A Good Deal for the Promising CAR-T
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, started book building to raise up to USD 368 million via an IPO. The company has a...
Ke Yan, CFA, FRM
Follow
505 Views
Share
bullish
ā¢
NetEase Inc
ā¢
31 May 2020 13:49
ECM Weekly (31 May 2020) - JD & NetEase HK, Legend Biotech, Burning Rock, Dada Nexus, Kangji
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. As per...
Zhen Zhou, Toh
531 Views
Share
bullish
ā¢
Legend Biotech Corp
ā¢
26 May 2020 14:14
Legend Biotech (ä¼ å„ēē©) Pre-IPO: Superior Efficacy Vs Bluebird/BMS Candidate
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, is planning to raise up to USD 300 million via an IPO. The company has a strong focus...
Ke Yan, CFA, FRM
Follow
509 Views
Share
bullish
ā¢
NetEase Inc
ā¢
24 May 2020 14:20
ECM Weekly (24 May 2020) - NetEase and JD Homecoming, Legend Biotech, Nongfu Spring, Yeahka
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. The talk...
Zhen Zhou, Toh
433 Views
Share
bullish
ā¢
Legend Biotech Corp
ā¢
19 May 2020 12:14
Legend Biotech (ä¼ å„ēē©) Pre-IPO: All-Stars Except for the Small Indication
Legend Biotech, a subsidiary of Hong Kong-listed GenScript, is planning to raise up to USD 300 million via an IPO. The company has a strong focus...
Ke Yan, CFA, FRM
Follow
354 Views
Share
First
Previous
20
21
22
23
24
Next
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright Ā© 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x